ArticleCase reports in oncological medicine2026
Isolated Metachronous Splenic Metastasis of Lung Adenocarcinoma: Long-Term Survival After Splenectomy.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isolated Metachronous Splenic Metastasis of Lung Adenocarcinoma: Long-Term Survival After Splenectomy.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis to the spleen is an uncommon finding in lung cancer and is typically associated with multivisceral disseminated disease. Isolated splenic metastasis in patients with lung cancer is exceedingly rare, with only 50 cases reported in the literature. We report a case of an asymptomatic, metachronous, isolated splenic metastasis in a 66-year-old female patient diagnosed 18 months after resection of lung adenocarcinoma. The patient underwent diagnostic and therapeutic splenectomy and remained tumor-free for 14 years. To our knowledge, this represents the longest reported survival following an isolated splenic metastasis from lung cancer. This case suggests that in well-selected patients with isolated splenic involvement, aggressive local therapy such as splenectomy can be curative and may lead to exceptional long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.